Cited by 965Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 217 of the 218 references it cites were found in a registry or an index.

Combination cancer immunotherapies tailored to the tumour microenvironment

Smyth, Mark J., Ngiow, Shin Foong, Ribas, Antoni, Teng, Michele W. L.·2016·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2015.209

Open this paper in CoChat — free account

Abstract

Evidence suggests that cancer immunotherapy will be a major part of the combination treatment plan for many patients with many cancer types in the near future. There are many types of immune processes involving different antitumour and tumour-promoting leucocytes, and tumour cells use many strategies to evade the immune response. The tumour microenvironment can help determine which immune suppressive pathways become activated to restrain antitumour immunity. This includes immune checkpoint receptors on effector T-cells and myeloid cells, and release of inhibitory cytokines and metabolites. Therapeutic approaches that target these pathways, particularly immune-checkpoint receptors, can induce durable antitumour responses in patients with advanced-stage cancers, including melanoma. Nevertheless, many patients do not have a good response to monotherapy approaches and alternative strategies are required to achieve optimal therapeutic benefit. These strategies include eliminating the bulk of tumour cells to provoke tumour-antigen release and antigen-presenting cell (APC) function, using adjuvants to enhance APC function, and using agents that enhance effector-cell activity. In this Review, we discuss the stratification of the tumour microenvironment according to tumour-infiltrating lymphocytes and PD-L1 expression in the tumour, and how this stratification enables the design of optimal combination cancer therapies tailored to target different tumour microenvironments.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2015.209

Cites

217 of 217 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 retracted

TIGIT predominantly regulates the immune response via regulatory T cells
Kurtuluş, S., Sakuishi, K., Ngiow, S. F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 558
Self-citation
Retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T. J., Mok, S., Cass, A. A., Haynes, N. M., Kinross, K. M., Yagita∥, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 274
Self-citation
Retracted
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
Kohrt, H. E. K., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F. A., Czerwinski, D. K., Colevas, A. D., Weng, W., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
Retracted
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E. K., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A. M. S., Pachynski, R. K., Czerwinski, D. K., Coutre, S. E., et al. (2010) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
Retracted
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Show all 218 references

Sorted by citations

Items 401–500 of 965

Circumventing Myeloid-Derived Suppressor Cell-Mediated Immunosuppression Using an Oxygen-Generated and -Economized Nanoplatform
Zuo, H., Hou, Y., Yu, Y., Li, Z., Liu, H., Liu, C., He, J., & Miao, L. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c18180 · Cited by 36
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Fanale, D., Corsini, L. R., Scalia, R., Brando, C., Cucinella, A., Madonia, G., Dimino, A., Filorizzo, C., Barraco, N., Bono, M., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103597 · Cited by 37
Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
Liu, S., Li, J., Gu, L., Wu, K.-Z., & Hua, X. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s388075 · Cited by 36
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
Facchinetti, F., Marabelle, A., Rossi, G., Soria, J., Besse, B., & Tiseo, M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.027 · Cited by 37
PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis
Téglási, V., Pipek, O., Lózsa, R., Berta, K., Szüts, D., Harkó, T., Vadász, P., Rojkó, L., Döme, B., Bagó, A. G., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.05.008 · Cited by 35
TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer
Chen, Y., Huang, H., Li, Y., Xiao, W., Liu, Y., Chen, R., Zhu, Y., Zheng, X. W., Wu, C., & Chen, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832230 · Cited by 35
Recognizing and managing on toxicities in cancer immunotherapy
Liu, Y., Hui-fang, Y., Dong, S., Zhong, Y., & Hu, S. (2017) · Tumor Biology · doi:10.1177/1010428317694542 · Cited by 37
Regulating the Obesity-Related Tumor Microenvironment to Improve Cancer Immunotherapy
Fang, H., Wu, Y. D., Chen, L., Cao, Z., Deng, Z., Zhao, R., Zhang, L., Yang, Y., Liu, Z., & Chen, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c11159 · Cited by 33
Self‐Degradable Nanogels Reshape Immunosuppressive Tumor Microenvironment via Drug Repurposing Strategy to Reactivate Cytotoxic CD8+ T Cells
Tian, H., Li, W., Wang, G., Tian, Y., Yan, J., Zhou, S., Yu, X., Li, B., & Dai, Y. (2023) · Advanced Science · doi:10.1002/advs.202301661 · Cited by 34
Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy
Weng, J., Wang, Z., Hu, Z., Xu, W., Sun, J.-L., Wang, F., Zhou, Q., Liu, S., Xu, M., Xu, M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3106 · Cited by 35
Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma
Wang, X., Xiong, Z., Liu, Z., Huang, X., & Jiang, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-30072-x · Cited by 34
Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine
Mai, J., Li, Z., Xia, X., Zhang, J., Li, J., Liu, H., Shen, J., Ramirez, M., Li, F., Li, Z., et al. (2021) · Advanced Science · doi:10.1002/advs.202100166 · Cited by 32
Molecular profiling of core immune-escape genes highlights LCK as an immune-related prognostic biomarker in melanoma
Wang, F., Zheng, A., Zhang, D., Zou, T., Xiao, M., Chen, J., Wen, B., Wen, Q., Wu, X., Li, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1024931 · Cited by 34
“The complex regulatory network in the tumor immune microenvironment plays a key role in tumor progression (19, 20).”
Background
Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model
Dobson, C. C., Naing, T., Beug, S. T., Faye, M. D., Chabot, J., St‐Jean, M., Walker, D. E., LaCasse, E. C., Stojdl, D. F., Korneluk, R. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13849 · Cited by 36
“Indeed, many of the most promising cancer immunotherapies that are currently under investigation are tailored to the tumour microenvironment [32].”
Background
Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity
Kang, S., Mansurov, A., Kurtanich, T. R., Chun, H. R., Slezak, A. J., Volpatti, L. R., Chang, K., Wang, T., Alpar, A. T., Refvik, K. C., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh9879 · Cited by 34
“To increase response rates and overcome resistance to single-agent immunotherapy, combinatorial treatment with complimentary agents has emerged as a promising approach ( 4 – 6 ).”
NSUN6 mediates 5‐methylcytosine modification of METTL3 and promotes colon adenocarcinoma progression
Cui, Y., Lv, P., & Zhang, C. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23749 · Cited by 33
Cardiovascular immune‐related adverse events: Evaluation, diagnosis and management
Liu, Y., & Wu, W. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13326 · Cited by 33
Preoperative systemic immune-inflammation index and prognostic nutritional index predict prognosis of patients with pulmonary neuroendocrine tumors after surgical resection
He, H., Guo, W., Song, P., Liu, L., Zhang, G., Wang, Y., Qiu, B., Tan, F., Xue, Q., & Gao, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-19-4476 · Cited by 33
“Ann Transl Med 2020;8(10):630 | http://dx.”
Background
α-Cyperone inhibits the proliferation of human cervical cancer HeLa cells via ROS-mediated PI3K/Akt/mTOR signaling pathway
Pei, X.-D., Yao, H., Shen, L., Yang, Y., Lu, L., Xiao, J., Wang, X., He, Z., & Jiang, L. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173355 · Cited by 33
Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
Zhou, X., Du, J., Wang, H., Chen, C., Jiao, L., Cheng, X., Zhou, X., Chen, S., Gou, S., Zhao, W., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00638-2 · Cited by 33
Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy
Dai, X., Li, X., Liu, Y., & Yan, F. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110656 · Cited by 34
The new progress in cancer immunotherapy
Shimu, A. S., Wei, H.-X., Li, Q., Zheng, X., & Li, B. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00887-0 · Cited by 36
“In response to solid tumors, myeloid cells-derived immune cells such as regulatory T cells and tumor-associated macrophages (TAM) suppress the tumor-killing nature of cytotoxic lymphocytes such as CD8+ T cells and natural killer cells [136, 137].”
Background
Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer
Zhang, H., Ye, L., Yu, X., Jin, K., & Wu, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956984 · Cited by 34
“Chemotherapy combined with immunotherapy is predicted to reinforce and synergistically increase the antitumor effects of either therapy alone (115).”
Background
Firing up the cold tumors by targeting Vps34
Janji, B., Hasmim, M., Parpal, S., Berchem, G., & Noman, M. Z. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1809936 · Cited by 30
“Despite the exciting and encouraging clinical responses obtained, the majority of patients treated with anti-CTLA-4, anti-PD-1, or anti-PD-L1 monotherapy still show none or partial objective responses.(1) Therefore, to achieve durable tumor regression in melanoma and CRC patients, there is a strong need to design new…”
Background
Cervical cancer immune infiltration microenvironment identification, construction of immune scores, assisting patient prognosis and immunotherapy
Yao, S., Zhao, L., Chen, S., Wang, H., Gao, Y., Shao, N., Dai, M., & Cai, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1135657 · Cited by 38
“Immune checkpoint inhibitors have now received FDA approval for first- and second-line treatment for various cancers (21), and favorable effectiveness has been seen in patients with metastasis and recurrence (22), such as the cytokines interferon-alpha (20) , the inter leukin-2 (IL-2) (23) .”
Background
Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade
Wang, M., Huang, Y., Chen, M., Wang, W., Wu, F., Zhong, T., Chen, X., Wang, F., Li, Y., Yu, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007035 · Cited by 33
Tumor microenvironment ameliorative and adaptive nanoparticles with photothermal-to-photodynamic switch for cancer phototherapy
Zhang, L., Yu, Y., Ding, K., Ji, C., Zhang, D., Liang, P., Tang, B. Z., & Feng, G. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122771 · Cited by 33
Microbiome and Cancers, With Focus on Genitourinary Tumors
Cimadamore, A., Santoni, M., Massari, F., Gasparrini, S., Liang Cheng, C., Antonio Lopez-beltran, B., Montironi, R., & Scarpelli, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00178 · Cited by 32
“Primary resistance to Immune checkpoint inhibitors (ICIs) has been linked to different factors, including poor intrinsic antigenicity of malignant cells, lack of priming by potentially immunogenic pretreatment with radio-, or/and chemotherapy (17), poor antigen presentation at the time of the priming phase (18), immun…”
Background
4-1BBL as a Mediator of Cross-Talk between Innate, Adaptive, and Regulatory Immunity against Cancer
Martínez-Pérez, A. G., Perez‐Trujillo, J. J., Garza-Morales, R., Loera‐Arias, M. D. J., Cárdenas, O. S., García‐García, A., Rodríguez‐Rocha, H., & Montes‐de‐Oca‐Luna, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126210 · Cited by 32
“Four distinct nodes can induce antitumoral immunity: eradicating the immune suppression in the tumor microenvironment, inducing immunogenic cancer cell death, enhancing the APC function/adjuvanticity, and enhancing T/macrophage effector activity [34].”
Background
Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
Ge, Y., Zhang, Y., Zhao, K., & Zhu, H. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s374672 · Cited by 32
“Smyth et al proposed four immune nodes that immunotherapy should target, namely, elimination of immune suppression, induction of immunogenic cancer cell death, enhancement of antigen presentation or adjuvanticity and stimulation of the activation and survival of immune effector cells.(21) Combinatorial immunotherapies…”
Background
Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis
Katoh, M. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.09.11 · Cited by 32
“Human/humanized monoclonal antibodies (mAbs), such as anti-HER2 mAb (trastuzumab), anti-PD-1 mAbs (pembrolizumab and nivolumab), anti-PD-L1 mAbs (atezolizumab, avelumab and durvalumab) and anti-vascular endothelial growth factor (VEGF) mAb (bevacizumab), are antibody-based drugs that are approved for the treatment of…”
Background
Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment
El-Osta, H. E., Shahid, K., Mills, G. M., & Peddi, P. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s111209 · Cited by 32
Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses
Oh, D. S., Kim, H., Oh, J. E., Jung, H. E., Lee, Y. S., Park, J., & Lee, H. K. (2017) · Oncotarget · doi:10.18632/oncotarget.17663 · Cited by 31
“Although our study focused on Tregs, other immune cells, such as myeloid-derived suppressor cells and tumorassociated macrophages, play immune-suppressive roles within tumor tissues [40].”
Background
Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: Enusage of plasticity
Nadella, V., Garg, M., Kapoor, S., Barwal, T. S., Jain, A., & Prakash, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-695 · Cited by 31
“Macrophages are heterogenous subset of immune cells within the TME and several recent studies have dissected their significant involvement in tumor progression, growth and metastasis.”
Influential
Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report
Obayashi, M., Shibasaki, Y., Koakutsu, T., Hayashi, Y., Shoji, T., Hirayama, K., Yamazaki, M., Takayanagi, Y., Shibata, H., Nakamura, M., et al. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01362-4 · Cited by 31
Palliative Radiofrequency Ablation Accelerates the Residual Tumor Progression Through Increasing Tumor-Infiltrating MDSCs and Reducing T-Cell-Mediated Anti-Tumor Immune Responses in Animal Model
Wu, H., Li, S., Zhou, M., Jiang, A., He, Y., Wang, S., Yang, W., & Liu, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01308 · Cited by 31
Lymphocyte‐activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epstein‐Barr virus‐positive and MLH1‐defective gastric cancer patients
Lv, K., Li, R., Cao, Y., Gu, Y., Liu, X., He, X., Jin, K., Fang, H., Fei, Y., Shi, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33358 · Cited by 32
“Recently, immunotherapy targeting the tumor immune microenvironment has created a new era of cancer treatment.(3) The result of KEYNOTE-059 trial(4) and CheckMate 032 study(5) showed that programmed cell death protein 1 (PD-1)/or its ligand (PD-L1) blockade did elicit a clinical benefit in gastric cancer.”
Background
Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival
Zhang, J., Wu, Z.-R., Zhao, J., Liu, S.-Y., Zhang, X., Yuan, F., Shi, Y.-J., & Song, B. (2020) · European Radiology · doi:10.1007/s00330-020-07524-y · Cited by 28
Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 32
TIM3+ cells in gastric cancer: clinical correlates and association with immune context
Chen, K., Gu, Y., Cao, Y., Fang, H., Lv, K., Liu, X., He, X., Wang, J., Lin, C., Liu, H., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01607-3 · Cited by 30
“Recent advances in immunotherapy, such as immune checkpoint (ICP) inhibitors, have provided novel opportunities for cancer treatment by targeting the tumour microenvironment (TME) to reinvigorate antitumor immunity [7].”
Background
MMP-responsive transformation nanomaterials with IAP antagonist to boost immune checkpoint therapy
Wang, T., He, Z., Yuan, C.-S., Deng, Z., Li, F., Chen, X., & Liu, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.018 · Cited by 31
Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma
Li, G., & Staveley-O’Carroll, K. F. (2016) · Journal of Clinical Trials · doi:10.4172/2167-0870.1000257 · Cited by 32
“Immunotherapy represents the most promising new approach in the treatment of cancers [12].”
Background
Icaritin and intratumoral injection of CpG treatment synergistically promote T cell infiltration and antitumor immune response in mice
Dongye, Z., Wu, X., Wen, Y., Ding, X., Wang, C., Zhao, T., Li, J., & Wu, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109093 · Cited by 31
MOF-based nanoparticles for tumor-targeted protein degradation and photodynamic therapy induce enhanced anti-tumor immunity
Zhu, H., Gao, F., Li, Y., Jiang, M., Zhang, Y., Chen, K., Han, L., Xue, S., Wang, K., Fan, Q., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102308 · Cited by 30
Enabling tumor-specific drug delivery by targeting the Warburg effect of cancer
Zhang, J., Pan, T., Lee, J., Goldberg, S., King, S. A., Tang, E., Hu, Y., Chen, L., Hoover, A., Zhu, L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101920 · Cited by 33
“77,78 Stimulator of interferon genes (STING) links innate immune responses to multiple downstream biological processes ranging from anti-tumor immunity to microbiome homeostasis.”
Progress of immune checkpoint therapy in the clinic (Review)
Fan, Y., Zhang, C., Jin, S., Gao, Z., Cao, J., Wang, A., Li, D., Wang, Q., Sun, X., & Bai, D. (2018) · Oncology Reports · doi:10.3892/or.2018.6819 · Cited by 30
“Combination therapies are in various stages of development (54), and personalized cancer vaccines hat enhance immune memory show promise (55); furthermore, biomarkers associated with resistance will be identified in additional research (53). ultimately, clinical activity will be optimized, and the…”
Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients
Ma, J., Sun, D., Wang, J., Han, C., Qian, Y., Chen, G., Li, X., Zhang, J., Cui, P., Du, W., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02452-3 · Cited by 30
Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study
Morgan, E., Suresh, A., Ganju, A., Stover, D. G., Wesolowski, R., Sardesai, S. D., Noonan, A. M., Reinbolt, R. E., VanDeusen, J. B., Williams, N. O., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1780-8 · Cited by 30
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)
You, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7643 · Cited by 31
“Recently, a new theory arose that according to both tumor‐infiltrating lymphocytes (TILs) and PD-L1 expression in tumors, the TME can be stratified into four groups: TILs-PD-L1-, TILs-PD-L1+, TILs+PD-L1- and TILs+PD-L1+ (88).”
Background
Mucosal Associated Invariant T Cells in Cancer-Friend or Foe?
O’Neill, C. A., Cassidy, F. C., O'Shea, D. B., & Hogan, A. E. (2021) · Cancers · doi:10.3390/cancers13071582 · Cited by 29
Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications
Li, Y., Wu, Y., & Hu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641883 · Cited by 31
CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
Ghallab, A. M., Eissa, R. A., & Tayebi, H. M. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.862125 · Cited by 32
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
Catalano, M., Shabani, S., Venturini, J., Ottanelli, C., Voltolini, L., & Roviello, G. (2022) · Cancers · doi:10.3390/cancers14246145 · Cited by 29
Immunostimulatory CpG on Carbon Nanotubes Selectively Inhibits Migration of Brain Tumor Cells
Alizadeh, D., White, E. E., Sanchez, T. C., Liu, S., Zhang, L., Badie, B., & Berlin, J. M. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00146 · Cited by 29
The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature
Chitsike, L., & Duerksen-Hughes, P. J. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00790-4 · Cited by 29
“clinically revolutionized the treatment of many cancers [10, 11].”
BackgroundInfluential
Expression Profile Analysis of m6A RNA Methylation Regulators Indicates They Are Immune Signature Associated and Can Predict Survival in Kidney Renal Cell Carcinoma
Fang, J., Hu, M., Sun, Y., Zhou, S., & Li, H. (2020) · DNA and Cell Biology · doi:10.1089/dna.2020.5767 · Cited by 29
“These immune microenvironment components constitute a complex regulatory network and play a pivotal role in tumorigenesis and development (Junttila and de Sauvage, 2013; Smyth et al. , 2016).”
Retinoic Acid Synthesis Deficiency Fosters the Generation of Polymorphonuclear Myeloid-Derived Suppressor Cells in Colorectal Cancer
Sun, H.-W., Chen, J., Wu, W., Yang, Y., Xu, Y.-T., Yu, X.-J., Chen, H., Wang, Z., Wu, X., & Zheng, L. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0389 · Cited by 29
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
Wang, Y., Sinha, S., Wellik, L. E., Secreto, C. R., Rech, K. L., Call, T. G., Parikh, S. A., Kenderian, S. S., Muchtar, E., Hayman, S. R., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00477-5 · Cited by 29
“Teng et al.26,27 proposed a model to classify tumor microenvironments based on PD-L1 expression in tumor cells and tumor infiltration lymphocytes (TIL), i.e., Type I, PDL1+, TIL+, indicating adaptive immune resistance; Type II, PD-L1−, TIL−, indicating immunological ignorance; Type III, PD-L1+, TIL−, indicating intrin…”
Background
Immune Checkpoint Inhibitors for Brain Metastases in Non-Small-Cell Lung Cancer: From Rationale to Clinical Application
Xiao, G., Liu, Z., Gao, X., Wang, H., Peng, H., Li, J., Yang, L., Duan, H., & Zhou, R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0262 · Cited by 32
MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy
Wan, J.-L., Wang, B., Wu, M.-L., Li, J., Gong, R.-M., Song, L.-N., Zhang, H., Zhu, G., Chen, S.-P., Cai, J., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215750 · Cited by 29
Engineered extracellular vesicles: A novel platform for cancer combination therapy and cancer immunotherapy
Ahmadi, M., Hassanpour, M., & Rezaie, J. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120935 · Cited by 30
Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status
Ashizawa, T., Iizuka, A., Maeda, C., Tanaka, E., Kondou, R., Miyata, H., Sugino, T., Kawata, T., Deguchi, S., Mitsuya, K., et al. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.10.003 · Cited by 29
Bimetal‐Biligand Frameworks for Spatiotemporal Nitric Oxide‐Enhanced Sono‐Immunotherapy
Cheng, Y., Zhong, W., Chen, Y., Tan, B. S. N., Zhao, Y., Guo, J., Ma, M., & Zhao, Y. (2024) · Advanced Materials · doi:10.1002/adma.202408242 · Cited by 28
Emerging role of checkpoint blockade therapy in lymphoma
Galanina, N., Kline, J. P., & Bishop, M. R. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716673787 · Cited by 34
An Antibody-like Polymeric Nanoparticle Removes Intratumoral Galectin-1 to Enhance Antitumor T-Cell Responses in Cancer Immunotherapy
Gu, Y. L., Zhao, Y., Zhang, Z., Hao, J., Zheng, Y., Liu, Q., Liu, Y., & Shi, L. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c02116 · Cited by 28
Nitric oxide-based multi-synergistic nanomedicine: an emerging therapeutic for anticancer
Tang, Y., Li, Q., Zhou, Z., Bai, H., Xiao, N., Xie, J., & Li, C. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02929-z · Cited by 27
“Additionally, while there have been advancements in immunotherapy techniques in recent years to boost the body’s immune response against tumors, treatment efficacy remains limited due to the tumor’s immune suppressive environment and the considerable differences between individuals [7–12].”
Background
In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1
Zhai, W., Zhou, X., Du, J., & Gao, Y. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.051 · Cited by 27
Imaging Beyond Seeing: Early Prognosis of Cancer Treatment
Shi, C., Zhou, Z., Lin, H., & Gao, J. (2020) · Small Methods · doi:10.1002/smtd.202001025 · Cited by 27
Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells
Tomogane, M., Sano, Y., Shimizu, D., Shimizu, T., Miyashita, M., Toda, Y., Hosogi, S., Tanaka, Y., Kimura, S. H., & Ashihara, E. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.005 · Cited by 27
Late-stage MC38 tumours recapitulate features of human colorectal cancer – implications for appropriate timepoint selection in preclinical studies
Shields, N. J., Peyroux, E. M., Ferguson, A. L., Steain, M. C., Neumann, S., & Young, S. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152035 · Cited by 31
“Accordingly, personalised combination strategies that are tailored to individual patients’ specific TMEs hold immense promise for the next generation of cancer immunotherapies (115).”
Background
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial
Shukuya, T., Asao, T., Goto, Y., Mimori, T., Takayama, K., Kaira, K., Tanaka, H., Ko, R., Amano, Y., TACHIHARA, M. Y., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00001-4 · Cited by 26
Emerging Biomarkers as Predictors to Anti-Pd1/PD-L1 Therapies in Advanced Melanoma
Loo, K. L., & DAUD, A. I. (2016) · Immunotherapy · doi:10.2217/imt-2016-0039 · Cited by 27
Methods for improving the immunogenicity and efficacy of cancer vaccines
Pilla, L., Ferrone, S., & Maccalli, C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1485649 · Cited by 27
“are synergistic with chemotherapy, vaccines, and other immunotherapeutic strategies [160].”
BackgroundInfluential
Surface-Enhanced Raman Spectroscopy for Cancer Immunotherapy Applications: Opportunities, Challenges, and Current Progress in Nanomaterial Strategies
Dey, S., Trau, M., & Koo, K. M. (2020) · Nanomaterials · doi:10.3390/nano10061145 · Cited by 26
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
Tsai, H., Han, M., Lin, Y., Chang, T., Chen, C., Cheng, P., Chuang, C., Wu, I., Chen, P., Kang, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02845-9 · Cited by 27
Emerging roles of purinergic signaling in anti-cancer therapy resistance
Zanoni, M., Pegoraro, A., Adinolfi, E., & Marchi, E. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1006384 · Cited by 26
“The introduction of checkpoint (programmed death 1/programmed death ligand 1, PD1/PDL1) or cytotoxic T lymphocyte-associated 4 (CTLA-4) inhibitors has substantially increased patients’ life expectancy (Ott et al., 2013; Smyth et al., 2016).”
Background
Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review
Alhamhoom, Y., Kakinani, G., Rahamathulla, M., Osmani, R. A. M., Hani, U., Thajudeen, K. Y., Raj, G. K., & Gowda, D. V. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.12.008 · Cited by 26
“Antibodies against programmed cell death protein 1 (PD1), IL-10, and cytotoxic T -lymphocyte–associated antigen 4 (CTLA-4) have contributed to the development of immunotherapy techniques (Smyth et al., 2015, Stewart and Keselowsky, 2017).”
Identification of a cancer associated fibroblasts-related index to predict prognosis and immune landscape in ovarian cancer
Ye, Y., Zhang, S., Jiang, Y., Huang, Y., Wang, G., Zhang, M., Gui, Z., Wu, Y., Bian, G., Li, P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48653-w · Cited by 25
18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors
Hicks, R. J., Iravani, A., & Sandhu, S. K. (2019) · PET Clinics · doi:10.1016/j.cpet.2019.08.007 · Cited by 25
Valproic Acid-Like Compounds Enhance and Prolong the Radiotherapy Effect on Breast Cancer by Activating and Maintaining Anti-Tumor Immune Function
Cai, Z., LIM, D. J., Liu, G., Chen, C., Jin, L., Duan, W., Ding, C., Sun, Q., Peng, J., Dong, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.646384 · Cited by 25
“Most solid tumors include a variety of immune cells, such as regulatory T cells and TAMs, which can inhibit CTLs function (22, 23).”
Background
Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis
Jiang, G., Ng, Y. Y., Tay, J. C.-K., Du, Z., Xiao, L., Wang, S., & Zhu, J. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03247-9 · Cited by 25
“The two therapeutic approaches target two different nodes to induce anti-tumor immunity [30].”
BackgroundInfluential
Near-infrared photoimmunotherapy and anti-cancer immunity
Nakajima, K., & Ogawa, M. (2023) · International Immunology · doi:10.1093/intimm/dxad042 · Cited by 27
Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas
Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 25
Bioresponsive nanoreactor initiates cascade reactions for tumor vascular normalization and lactate depletion to augment immunotherapy
Chen, J., Bu, C., Lu, Y., Peng, X., Yu, J., Ding, X., Yuan, P., & Hong, S. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123100 · Cited by 25
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 24
Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma
Wickenhauser, C., Bethmann, D., Kappler, M., Eckert, A. W., Steven, A., Bukur, J., Fox, B. A., Beer, J., & Seliger, B. (2021) · Cancers · doi:10.3390/cancers13040620 · Cited by 24
“List of abbreviations ALAS 1, delta-aminolevulinate synthase 1; APM, antigen processing machinery; β2-m, beta-2-microglobulin; CPI, checkpoint inhibitor; CRC, colorectal cancer; CSI, cumulative suppression index; CTL, cytotoxic T lymphocyte; DAB, 3,3'-diaminobenzidine; FFPE, formalin-fixed paraffin-embedded; FITC, flu…”
BackgroundInfluential
Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis
Jing, C., Fu, Y., Zhou, C., Zhang, M., Yi, Y., Huang, J., Gan, W., Zhang, J., Zheng, S.-S., Zhang, B., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01705-9 · Cited by 24
A size/charge/targeting changeable nano-booster to realize synergistic photodynamic-immunotherapy with high safety
Zang, J., He, R., Liu, Y., Su, R., Zhao, Y., Zheng, X. W., Liu, Y., Chong, G., Ruan, S., Wang, H., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.134585 · Cited by 24
Advancements in technology for characterizing the tumor immune microenvironment
Yan, H., Ju, X., Huang, A., & Yuan, J. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.92525 · Cited by 24
“This proposed classification may be important for designing optimal immunotherapeutic strategies [28, 29].”
Background
The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018
Dahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
Establishment and characterization of a mouse tumor cell line with irreversible downregulation of MHC class I molecules
Lhotáková, K., Grzelak, A., Poláková, I., Vackova, J., & Šmahel, M. (2019) · Oncology Reports · doi:10.3892/or.2019.7356 · Cited by 23
“The efficacy of cancer immunotherapy may be enhanced by a combination of different immunotherapeutic approaches that include activation of both adaptive and innate immunity and inhibition of immunosuppressive mechanisms (6,7).”
Background
Multifunctional Nanomodulators Regulate Multiple Pathways To Enhance Antitumor Immunity
Zheng, Y., Zhang, Z., Liu, Q., Zhao, Y., Zheng, C., Hao, J., Yi, K., Wang, Y., Wang, C., Zhao, X., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00513 · Cited by 23
Necroptosis-elicited host immunity: GOx-loaded MoS2 nanocatalysts for self-amplified chemodynamic immunotherapy
Xie, W., Lu, J., Guo, Z., Guo, X., Chi, Y., Ye, J., Zhang, J., Xu, W., Zhao, L., & Wei, Y. (2021) · Nano Research · doi:10.1007/s12274-021-3763-7 · Cited by 24
“Currently, nanoparticle-based cancer immunotherapy, a strategy by activating the immune system and enhancing its adaptive power for cancer treatment via nanoparticles, has been considered as one of the most promising treatments for cancer therapy [2, 3].”
Background
Multifunctional Immunoliposomes Enhance the Immunotherapeutic Effects of PD‐L1 Antibodies against Melanoma by Reprogramming Immunosuppressive Tumor Microenvironment
Hei, Y., Yang, C., Li, Q., Mei, Z., Pan, J., Zhang, S., Xiong, C., Su, X., & Wei, S. (2021) · Small · doi:10.1002/smll.202105118 · Cited by 23
Analysis of Ferroptosis-Related LncRNAs Signatures Associated with Tumor Immune Infiltration and Experimental Validation in Clear Cell Renal Cell Carcinoma
Chen, X., Tu, J., Ma, L., Huang, Y., Yang, C., & Yuan, X. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s354682 · Cited by 23
“Exploring the Immune Characteristics of the Two ccRCC Clusters It is also well-known about the existence of complicated interactive networks in tumor microenvironment that contain tumor-infiltrating immune cells, and more significantly, profile of immune infiltration has profound effects on tumorigenesis and progressi…”
Background
The CXCL10/CXCR3 Pathway Contributes to the Synergy of Thermal Ablation and PD-1 Blockade Therapy against Tumors
Xiao, W., Huang, H., Zheng, P., Liu, Y., Chen, Y., Chen, J., Zheng, X. W., Chen, L., & Jiang, J. (2023) · Cancers · doi:10.3390/cancers15051427 · Cited by 24
Immuno-Oncology: The Third Paradigm in Early Drug Development
Martín-Liberal, J., Hierro, C., de Olza, M. O., & Rodon, J. A. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0471-4 · Cited by 24
MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models
Fiedler, U., Ekawardhani, S., Cornelius, A., Gilboy, P., Bakker, T. R., Dolado, I., Stumpp, M. T., & Dawson, K. M. (2017) · Oncotarget · doi:10.18632/oncotarget.21738 · Cited by 23
“Further, the enhancement of anti-PD1 efficacy by MP0250 (Figure 6) indicates the potential for combination therapy with the immunetherapeutic molecules that are currently revolutionizing cancer therapy [38].”
Background
Oral hygiene might prevent cancer
Cordero, O. J., & Varela‐Calviño, R. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00879 · Cited by 25
“environmental agents that can alter the commensal microbiota [7, 11, 13, 14, 15, 16].”
BackgroundInfluential
Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival
Sorrentino, C., Yin, Z., Ciummo, S. L., Lanuti, P., Lu, L., Marchisio, M., Bellone, M., & Carlo, E. D. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0668-z · Cited by 23

Authors: Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L.
Affiliations: QIMR Berghofer Medical Research Institute (AU)
University of California, Los Angeles (US)
Corresponding author: Teng, Michele W. L.
ORCID: Smyth, Mark J.
Ngiow, Shin Foong
Ribas, Antoni
Teng, Michele W. L.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2015-11-24
Volume: 13
Issue: 3
Pages: 143-158
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2015.209
OpenAlex: W2257916459
Cited by: 944
References: 218
Citations by year: 2026: 28 · 2025: 50 · 2024: 71 · 2023: 82 · 2022: 132 · 2021: 102 · 2020: 134 · 2019: 95 · 2018: 99 · 2017: 89 · 2016: 56 · 2015: 3
FWCI: 8.83
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Bristol-Myers Squibb
Kite Pharma
National Cancer Institute (R35CA197633)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, combination therapy, tumor microenvironment, immune evasion, immune checkpoint receptors, PD-L1, tumor-infiltrating lymphocytes, myeloid cells, inhibitory cytokines, antigen-presenting cells, adjuvants, melanoma
MeSH terms: Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Immunotherapy, Neoplasms, Signal Transduction, Treatment Outcome, Tumor Escape, Molecular Targeted Therapy, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combination cancer immunotherapies tailored to the tumour microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks